Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer’s disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To further eluc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wojtas, Aleksandra M., Carlomagno, Yari, Sens, Jonathon P., Kang, Silvia S., Jensen, Tanner D., Kurti, Aishe, Baker, Kelsey E., Berry, Taylor J., Phillips, Virginia R., Castanedes, Monica Casey, Awan, Ayesha, DeTure, Michael, De Castro, Cristhoper H. Fernandez, Librero, Ariston L., Yue, Mei, Daughrity, Lillian, Jansen-West, Karen R., Cook, Casey N., Dickson, Dennis W., Petrucelli, Leonard, Fryer, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708249/
https://www.ncbi.nlm.nih.gov/pubmed/33261653
http://dx.doi.org/10.1186/s40478-020-01079-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708249/
https://www.ncbi.nlm.nih.gov/pubmed/33261653
http://dx.doi.org/10.1186/s40478-020-01079-1

Ejemplares similares